To cleave or not and how? The DNA exonucleases and endonucleases in immunity
), Teng Maa()Abstract
DNA exonucleases and endonucleases are key executors of the genome during many physiological processes. They generate double-stranded DNA by cleaving damaged endogenous or exogenous DNA, triggering the activation of the innate immune pathways such as cGAS-STING-IFN, and enabling the body to produce anti-viral or anti-tumor immune responses. This is of great significance for maintaining the stability of the genome and improving the therapeutic efficacy of tumors. In addition, genomic instability caused by exonuclease mutations contributes to the development of various autoimmune diseases. This review summarizes the DNA exonucleases and endonucleases which have critical functions in immunity and associated diseases.
References
Shevelev IV, Hübscher U. The 3’–5’ exonucleases. Nat Rev Mol Cell Biol. 2002;3(5):364-376.
Reams AB, Roth JR. Mechanisms of gene duplication and amplification. Cold Spring Harbor Perspect Biol. 2015;7(2):a016592.
Wu CC, Lin JLJ, Yang-Yen HF, Yuan HS. A unique exonuclease ExoG cleaves between RNA and DNA in mitochondrial DNA replication. Nucleic Acids Res. 2019;47(10):5405-5419.
Young MJ, Copeland WC. Human mitochondrial DNA replication machinery and disease. Curr Opin Genet Dev. 2016;38:52-62.
Wang YT, Yang WJ, Li CL, Doudeva LG, Yuan HS. Structural basis for sequence-dependent DNA cleavage by nonspecific endonucleases. Nucleic Acids Res. 2006;35(2):584-594.
Mason PA, Cox LS. The role of DNA exonucleases in protecting genome stability and their impact on ageing. Age. 2012;34(6):1317-1340.
Cejka P, Symington LS. DNA end resection: mechanism and control. Annu Rev Genet. 2021;55:285-307.
Ranjha L, Howard SM, Cejka P. Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes. Chromosoma. 2018;127(2):187-214.
Symington LS, Gautier J. Double-strand break end resection and repair pathway choice. Annu Rev Genet. 2011;45:247-271.
Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS–STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021;21(9):548-569.
Li Y, Shen Y, Jin K, et al. The DNA repair nuclease MRE11A functions as a mitochondrial protector and prevents T cell pyroptosis and tissue inflammation. Cell Metabol. 2019;30(3):477-492.e6.
Crow YJ, Hayward BE, Parmar R, et al. Mutations in the gene encoding the 3’-5’ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat Genet. 2006;38(8):917-920.
Lee-Kirsch MA, Gong M, Chowdhury D, et al. Mutations in the gene encoding the 3’-5’ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39(9):1065-1067.
Sun Z, Hornung V. cGAS-STING signaling. Curr Biol. 2022;32(13):R730-R734.
Liu X, Wang XS, Lee BJ, et al. CtIP is essential for early B cell proliferation and development in mice. J Exp Med. 2019;216(7):1648-1663.
Ajimura M, Leem SH, Ogawa H. Identification of new genes required for meiotic recombination in Saccharomyces cerevisiae. Genetics. 1993;133(1):51-66.
Hopfner KP, Karcher A, Craig L, Woo TT, Carney JP, Tainer JA. Structural biochemistry and interaction architecture of the DNA double-strand break repair Mre11 nuclease and Rad50-ATPase. Cell. 2001;105(4):473-485.
Paull TT. 20 years of Mre11 biology: No end in sight. Mol Cell. 2018;71(3):419-427.
Paull TT. Mechanisms of ATM activation. Annu Rev Biochem. 2015;84:711-738.
Uziel T. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J. 2003;22(20):5612-5621.
Mimitou EP, Symington LS. Sae2, Exo 1 and Sgs1 collaborate in DNA double-strand break processing. Nature. 2008;455(7214):770-774.
Shibata A, Moiani D, Arvai AS, et al. DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities. Mol Cell. 2014;53(1):7-18.
von Morgen P, Burdova K, Flower TG, et al. MRE11 stability is regulated by CK2-dependent interaction with R2TP complex. Oncogene. 2017;36(34):4943-4950.
Stewart GS, Maser RS, Stankovic T, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an Ataxia-telangiectasia-like disorder. Cell. 1999;99(6):577-587.
Bartkova J, Tommiska J, Oplustilova L, et al. Aberrations of the MRE11–RAD50–NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol. 2008;2(4):296-316.
Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.
Shiloh Y, Kastan MB. ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res. 2001;83:209-254.
Taylor AMR, Groom A, Byrd PJ. Ataxia-telangiectasia-like disorder (ATLD) — its clinical presentation and molecular basis. DNA Repair. 2004;3(8–9):1219-1225.
Paull TT, Gellert M. The 3’ to 5’ exonuclease activity of Mre11 facilitates repair of DNA double-strand breaks. Mol Cell. 1998;1(7):969-979.
Kondo T, Kobayashi J, Saitoh T, et al. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A. 2013;110(8):2969-2974.
Lee L, Perez Oliva AB, Martinez-Balsalobre E, et al. UFMylation of MRE11 is essential for telomere length maintenance and hematopoietic stem cell survival. Sci Adv. 2021;7(39):eabc7371.
Lee L, Perez Oliva AB, Martinez-Balsalobre E, et al. UFMylation of MRE11 is essential for telomere length maintenance and hematopoietic stem cell survival. Sci Adv. 2021;7(39):eabc7371.
Dmitrieva NI, Malide D, Burg MB. Mre11 is expressed in mammalian mitochondria where it binds to mitochondrial DNA. Am J Physiol Regul Integr Comp Physiol. 2011;301(3):R632-R640.
Li Y, Goronzy JJ, Weyand CM. DNA damage, metabolism and aging in pro-inflammatory T cells: rheumatoid arthritis as a model system. Exp Gerontol. 2018;105:118-127.
Luzwick JW, Dombi E, Boisvert RA, et al. MRE11-dependent instability in mitochondrial DNA fork protection activates a cGAS immune signaling pathway. Sci Adv. 2021;7(51):eabf9441.
Niraj J, Färkkilä A, D’Andrea AD. The fanconi Anemia pathway in cancer. Annu Rev Cell Biol. 2019;3:457-478.
Zhang X, Shaw A, Bates PA, et al. Structure of the AAA ATPase p97. Mol Cell. 2000;6(6):1473-1484.
Kilgas S, Singh AN, Paillas S, et al. p97/VCP inhibition causes excessive MRE11-dependent DNA end resection promoting cell killing after ionizing radiation. Cell Rep. 2021;35(8):109153.
Tishkoff DX, Amin NS, Viars CS, Arden KC, Kolodner RD. Identification of a human gene encoding a homologue of Saccharomyces cerevisiae EXO1, an exonuclease implicated in mismatch repair and recombination. Cancer Res. 1998;58(22):5027-5031.
Keijzers G, Bakula D, Petr MA, et al. Human exonuclease 1 (EXO1) regulatory functions in DNA replication with putative roles in cancer. Int J Mol Sci. 2018;20(1):74.
Manhart CM, Alani E. Roles for mismatch repair family proteins in promoting meiotic crossing over. DNA Repair. 2016;38:84-93.
Zhang Y, Yuan F, Presnell SR, et al. Reconstitution of 5’-directed human mismatch repair in a purified system. Cell. 2005;122(5):693-705.
Cannavo E, Cejka P, Kowalczykowski SC. Relationship of DNA degradation by Saccharomyces cerevisiae exonuclease 1 and its stimulation by RPA and Mre11-Rad50-Xrs2 to DNA end resection. Proc Natl Acad Sci U S A. 2013;110(18):E1661-E1668.
Guan J, Lu C, Jin Q, et al. MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway. Cancer Cell. 2021;39(1):109-121.e5.
Sveen A, Johannessen B, Tengs T, et al. Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Med. 2017;9(1):46.
Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819-829.
Brosh Jr RM, Waheed J, Sommers JA. Biochemical characterization of the DNA substrate specificity of Werner syndrome helicase. J Biol Chem. 2002;277(26):23236-23245.
Yu CE, Oshima J, Fu YH, et al. Positional cloning of the Werner’s syndrome gene. Science. 1996;272(5259):258-262.
Fang EF, Hou Y, Lautrup S, et al. NAD+ augmentation restores mitophagy and limits accelerated aging in Werner syndrome. Nat Commun. 2019;10(1):5284.
Oshima J, Sidorova JM, Jr Monnat RJ. Werner syndrome: clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev. 2017;33:105-114.
Talaei F, van Praag VM, Henning RH. Hydrogen sulfide restores a normal morphological phenotype in Werner syndrome fibroblasts, attenuates oxidative damage and modulates mTOR pathway. Pharmacol Res. 2013;74:34-44.
Lieb S, Blaha-Ostermann S, Kamper E, et al. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. Elife. 2019;8:e43333.
Chan EM, Shibue T, McFarland JM, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019;568(7753):551-556.
van Wietmarschen N, Sridharan S, Nathan WJ, et al. Repeat expansions confer WRN dependence in microsatellite-unstable cancers. Nature. 2020;586(7828):292-298.
Datta A, Biswas K, Sommers JA, et al. WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells. Nat Commun. 2021;12(1):6561.
Kategaya L, Perumal SK, Hager JH, Belmont LD. Werner syndrome helicase is required for the survival of cancer cells with microsatellite instability. iScience. 2019;13:488-497.
Futami K, Furuichi Y. RECQL1 and WRN DNA repair helicases: potential therapeutic targets and proliferative markers against cancers. Front Genet. 2015;5:441.
Mazur DJ, Perrino FW. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3’→5’ exonucleases. J Biol Chem. 1999;274(28):19655-19660.
Mazur DJ, Perrino FW. Structure and expression of the TREX1 and TREX2 3’→5’ exonuclease genes. J Biol Chem. 2001;276(18):14718-14727.
Mukherjee S, Abdisalaam S, Bhattacharya S, Srinivasan K, Sinha D, Asaithamby A. Mechanistic link between DNA damage sensing, repairing and signaling factors and immune signaling. Adv Protein Chem Struct Biol. 2019;115:297-324.
Rice G, Newman WG, Dean J, et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet. 2007;80(4):811-815.
Lehtinen DA, Harvey S, Mulcahy MJ, Hollis T, Perrino FW. The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease. J Biol Chem. 2008;283(46):31649-31656.
Xiao N, Wei J, Xu S, et al. cGAS activation causes lupus-like autoimmune disorders in a TREX1 mutant mouse model. J Autoimmun. 2019;100:84-94.
Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008;134(4):587-598.
Crow YJ, Manel N. Aicardi-Goutières syndrome and the type I interferonopathies. Nat Rev Immunol. 2015;15(7):429-440.
Zhou W, Mohr L, Maciejowski J, Kranzusch PJ. cGAS phase separation inhibits TREX1-mediated DNA degradation and enhances cytosolic DNA sensing. Mol Cell. 2021;81(4):739-755.e7.
Gao D, Li T, Li XD, et al. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. Proc Natl Acad Sci U S A. 2015;112(42):E5699-E5705.
Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.
Vanpouille-Box C, Formenti SC, Demaria S. TREX1 dictates the immune fate of irradiated cancer cells. OncoImmunology. 2017;6(9):e1339857.
Mohr L, Toufektchan E, von Morgen P, Chu K, Kapoor A, Maciejowski J. ER-directed TREX1 limits cGAS activation at micronuclei. Mol Cell. 2021;81(4):724-738.e9.
Srivastava N, Nader GPF, Williart A, et al. Nuclear fragility, blaming the blebs. Curr Opin Cell Biol. 2021;70:100-108.
de Freitas Nader GP, Agüera-Gonzalez S, Routet F, et al. Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion. Cell. 2021;184(20):5230-5246.e22.
Schaeper U, Subramanian T, Lim L, Boyd JM, Chinnadurai G. Interaction between a cellular protein that binds to the C-terminal region of adenovirus E1A (CtBP) and a novel cellular protein is disrupted by E1A through a conserved PLDLS motif. J Biol Chem. 1998;273(15):8549-8552.
Yun MH, Hiom K. CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature. 2009;459(7245):460-463.
Nakamura K, Kogame T, Oshiumi H, et al. Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair. PLoS Genet. 2010;6(1):e1000828.
Reczek CR, Szabolcs M, Stark JM, Ludwig T, Baer R. The interaction between CtIP and BRCA1 is not essential for resection-mediated DNA repair or tumor suppression. J Cell Biol. 2013;201(5):693-707.
Polato F, Callen E, Wong N, et al. CtIP-mediated resection is essential for viability and can operate independently of BRCA1. J Exp Med. 2014;211(6):1027-1036.
Sartori AA, Lukas C, Coates J, et al. Human CtIP promotes DNA end resection. Nature. 2007;450(7169):509-514.
Jensen KL, Russell P. Ctp1-dependent clipping and resection of DNA double-strand breaks by Mre11 endonuclease complex are not genetically separable. Nucleic Acids Res. 2016;44(17):8241-8249.
Williams RS, Dodson GE, Limbo O, et al. Nbs1 flexibly tethers Ctp1 and Mre11-Rad50 to coordinate DNA double-strand break processing and repair. Cell. 2009;139(1):87-99.
Anand R, Ranjha L, Cannavo E, Cejka P. Phosphorylated CtIP functions as a co-factor of the MRE11-RAD50-NBS1 endonuclease in DNA end resection. Mol Cell. 2016;64(5):940-950.
Anand R, Jasrotia A, Bundschuh D, et al. NBS1 promotes the endonuclease activity of the MRE11-RAD50 complex by sensing CtIP phosphorylation. EMBO J. 2019;38(7):e101005.
Kousholt AN, Fugger K, Hoffmann S, et al. CtIP-dependent DNA resection is required for DNA damage checkpoint maintenance but not initiation. J Cell Biol. 2012;197(7):869-876.
Harrington JJ, Lieber MR. The characterization of a mammalian DNA structure-specific endonuclease. EMBO J. 1994;13(5):1235-1246.
Balakrishnan L, Bambara RA. Flap endonuclease 1. Annu Rev Biochem. 2013;82:119-138.
Saharia A, Guittat L, Crocker S, et al. Flap endonuclease 1 contributes to telomere stability. Curr Biol. 2008;18(7):496-500.
Teasley DC, Parajuli S, Nguyen M, et al. Flap endonuclease 1 limits telomere fragility on the leading strand. J Biol Chem. 2015;290(24):15133-15145.
Xian H, Watari K, Sanchez-Lopez E, et al. Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling. Immunity. 2022;55(8):1370-1385.e8.
Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol. 2015;15(12):760-770.
Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17(10):1142-1149.
Ablasser A, Chen ZJ. cGAS in action: expanding roles in immunity and inflammation. Science. 2019;363(6431):eaat8657.
Kucherlapati M, Yang K, Kuraguchi M, et al. Haploinsufficiency of Flap endonuclease (Fen 1) leads to rapid tumor progression. Proc Natl Acad Sci U S A. 2002;99(15):9924-9929.
Zheng L, Jia J, Finger LD, Guo Z, Zer C, Shen B. Functional regulation of FEN1 nuclease and its link to cancer. Nucleic Acids Res. 2011;39(3):781-794.
Wang K, Xie C, Chen D. Flap endonuclease 1 is a promising candidate biomarker in gastric cancer and is involved in cell proliferation and apoptosis. Int J Mol Med. 2014;33(5):1268-1274.
He L, Luo L, Zhu H, et al. FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer. Mol Oncol. 2017;11(6):640-654.
Wang S, Wang X, Sun J, et al. Down-regulation of DNA key protein-FEN1 inhibits OSCC growth by affecting immunosuppressive phenotypes via IFN-γ/JAK/STAT-1. Int J Oral Sci. 2023;15:17.
Boddy MN, Gaillard PHL, McDonald WH, Shanahan P, Yates JR, Russell P. Mus 81-Eme1 are essential components of a Holliday junction resolvase. Cell. 2001;107(4):537-548.
Chen XB, Melchionna R, Denis CM, et al. Human Mus 81-associated endonuclease cleaves Holliday junctions in vitro. Mol Cell. 2001;8(5):1117-1127.
Wyatt HDM, West SC. Holliday junction resolvases. Cold Spring Harbor Perspect Biol. 2014;6(9):a023192.
Wyatt HDM, Sarbajna S, Matos J, West SC. Coordinated actions of SLX1-SLX4 and MUS81-EME1 for Holliday junction resolution in human cells. Mol Cell. 2013;52(2):234-247.
Brégnard C, Guerra J, Déjardin S, Passalacqua F, Benkirane M, Laguette N. Upregulated LINE-1 activity in the fanconi Anemia cancer susceptibility syndrome leads to spontaneous pro-inflammatory cytokine production. EBioMedicine. 2016;8:184-194.
Laguette N, Brégnard C, Hue P, et al. Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell. 2014;156(1–2):134-145.
Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol. 2010;11(11):1005-1013.
Rice GI, Bond J, Asipu A, et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet. 2009;41(7):829-832.
Hanada K, Budzowska M, Davies SL, et al. The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks. Nat Struct Mol Biol. 2007;14:1096-1104.
Ho SSW, Zhang WYL, Tan NYJ, et al. The DNA structure-specific endonuclease MUS81 mediates DNA sensor STING-dependent host rejection of prostate cancer cells. Immunity. 2016;44(5):1177-1189.
Li C, Shen Q, Zhang P, et al. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells. J Exp Clin Cancer Res. 2021;40(1):315.
Agrawal A, Eastman QM, Schatz DG. Transposition mediated by RAG1 and RAG2 and its implications for the evolution of the immune system. Nature. 1998;394(6695):744-751.
Villa A, Santagata S, Bozzi F, Imberti L, Notarangelo LD. Omenn syndrome: a disorder of Rag1 and Rag2 genes. J Clin Immunol. 1999;19(2):87-97.
Notarangelo LD, Kim MS, Walter JE, Lee YN. Human RAG mutations: biochemistry and clinical implications. Nat Rev Immunol. 2016;16:234-246.
Liu C, Zhang Y, Liu CC, Schatz DG. Structural insights into the evolution of the RAG recombinase. Nat Rev Immunol. 2022;22(6):353-370.
Lescale C, Deriano L. The RAG recombinase: beyond breaking. Mech Ageing Dev. 2017;165:3-9.
IJspeert H, Driessen GJ, Moorhouse MJ, et al. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes. J Allergy Clin Immunol. 2014;133(4):1124-1133.e1.
Lee YN, Frugoni F, Dobbs K, et al. Characterization of T and B cell repertoire diversity in patients with RAG deficiency. Sci Immunol. 2016;1(6):eaah6109.
Huang DCS, Strasser A. BH3-only proteins — essential initiators of apoptotic cell death. Cell. 2000;103(6):839-842.
Gratia M, Rodero MP, Conrad C, et al. Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS. J Exp Med. 2019;216(5):1199-1213.
Delbridge ARD, Pang SHM, Vandenberg CJ, et al. RAG-induced DNA lesions activate proapoptotic BIM to suppress lymphomagenesis in p53-deficient mice. J Exp Med. 2016;213(10):2039-2048.
Oh JM, Kang Y, Park J, et al. MSH2-MSH3 promotes DNA end resection during homologous recombination and blocks polymerase theta-mediated end-joining through interaction with SMARCAD1 and EXO1. Nucleic Acids Res. 2023;51(11):5584-5602.
Surtees JA, Alani E. Mismatch repair factor MSH2-MSH3 binds and alters the conformation of branched DNA structures predicted to form during genetic recombination. J Mol Biol. 2006;360(3):523-536.
Franchitto A, Pirzio LM, Prosperi E, Sapora O, Bignami M, Pichierri P. Replication fork stalling in WRN-deficient cells is overcome by prompt activation of a MUS81-dependent pathway. J Cell Biol. 2008;183(2):241-252.
Lemaçon D, Jackson J, Quinet A, et al. MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells. Nat Commun. 2017;8(1):860.
京公网安备11010802044758号